ERT Announces Availability of Insights Cloud
PHILADELPHIA – April 16, 2015 –– ERT, a leading global solutions provider for high-quality patient safety and efficacy endpoint data collection, today announced the launch of the Insights Cloud™, a suite of data analytics, visualization, and workflow applications that leverage real-time clinical trials data to provide clinical trial sponsors and CROs with actionable insights and process optimization. EXPERT Central™ - ERT's proprietary Research & Integration platform - includes an eClinical data hub for integrating and harmonizing clinical trials data from any clinical system. The integration framework includes standard adapters to leading electronic data capture (EDC) solutions such as Medidata Rave® and Oracle InForm®, and facilitates the real-time exchange of clinical trials data.
“As the clinical research industry continues to struggle with the proliferation of data silos, ERT has been evaluating how best to help our customers overcome the challenges of data fragmentation,” states Jim Corrigan, President and CEO of ERT. “Since our acquisition of eClinical Insights in 2014, we have been incorporating their innovative integration technology to support this mission, and are excited to release this first-in-class platform that provides our customers with capabilities for accessing, sharing, and integrating their clinical trials data."
By extending the proven ERT EXPERT platform with eClinical Insight’s integration technology, trial sponsors and CROs will benefit from the rapid deployment of the ERT EXPERT Central data integration layer that enables real-time data exchange between systems. The end result is comprehensive insight into investigative site and outcomes data activity across all spectrums of clinical and operational data. The ERT Insights Cloud now offers site selection, true risk-based management, enhanced performance measurement, and informed real-time decision-making.
“This is the first of many initiatives at ERT to help our customers leverage our solutions to enable data-driven trial management strategies,” said Amy Furlong, Executive Vice President, Cardiac Safety and Insights Solutions at ERT. “With the global and diverse nature of clinical trials today, the ERT Insights Cloud is the only solution that crosses the boundaries of disparate technology and disconnected teams by centralizing data, harmonizing workflow, and delivering a fully integrated business intelligence solution. In addition, with our forty plus years of experience and vast amount of current and historical site performance metrics, we are now assisting sponsors and CROs in site selection and performance management.”
ERT representatives will demonstrate the ERT Insights Cloud at the BioIT World Conference and Expo, booth #154, in Boston, MA beginning Monday, April 20.
For more information on the ERT Insights Cloud and EXPERT Central, visit here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
